DSP-2342 for Schizophrenia
What You Need to Know Before You Apply
What is the purpose of this trial?
The investigators aim to determine the effects of a novel drug on brain function and brain chemistry in patients with schizophrenia.
Who Is on the Research Team?
Akira Sawa, MD
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for adults diagnosed with schizophrenia who are able to participate in brain imaging studies. People with certain medical conditions or other factors that could interfere with the study may not be eligible.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- DSP-2342
Trial Overview
The study is testing a new drug called DSP-2342 to see how it affects brain function and chemistry in people with schizophrenia, using brain imaging techniques.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
The primary goal of this study is to evaluate the neural effects of a single oral dose of DSP-2342 on brain chemistry and brain activity in adults with schizophrenia. The investigators will measure brain chemistry using magnetic resonance spectroscopy and brain activity using task-based functional MRI. The investigators will compare these measures before and after a single dose of DSP-2342.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
Sumitomo Pharmaceuticals America
Industry Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.